Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial

Diabetologia

Volumn 59, Issue 6, 2016, Pages 1153-1161

  Gitelman, Stephen E ^a   Gottlieb, Peter A ^b   Felner, Eric I ^c   Willi, Steven M ^d,e   Fisher, Lynda K ^f   Moran, Antoinette ^g   Gottschalk, Michael ^h   Moore, Wayne V ⁱ   Pinckney, Ashley ^j   Keyes Elstein, Lynette ^j   Harris, Kristina M ^k   Kanaparthi, Sai ^k   Phippard, Deborah ^k,l   Ding, Linna ^m   Bluestone, Jeffrey A ^a   Ehlers, Mario R ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

ⁱ UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^j Rho Federal Systems Division Inc   (United States)

^k Immune Tolerance Network   (United States)

^l Precision for Medicine   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁿ Immune Tolerance Network   (United States)

more..

Author keywords

ATG; Beta cells; C peptide; START trial; T cells; Thymoglobulin; Tregs; Type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; PLACEBO; THYMOCYTE ANTIBODY; ANTIDIABETIC AGENT; LYMPHOCYTE ANTIBODY;

ACNE; ADOLESCENT; ADULT; ALLERGY; ARTHRALGIA; ARTICLE; BACKACHE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTACT DERMATITIS; CONTROLLED STUDY; COUGHING; CYTOKINE RELEASE SYNDROME; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DIABETIC KETOACIDOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EPSTEIN BARR VIRUS INFECTION; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; LONG TERM CARE; LYMPHOCYTOPENIA; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OPPORTUNISTIC INFECTION; OROPHARYNX PAIN; PANCREAS ISLET CELL FUNCTION; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SERUM SICKNESS; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOMITING; YOUNG ADULT; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNITY, HUMORAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962673275     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3917-4     Document Type: Article

References (22)

1. Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300
2. The Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37:1574–1582
3. Feutren G, Papoz L, Assan R et al (1986) Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2:119–124
4. Orban T, Bundy B, Becker DJ et al (2014) Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37:1069–1075
5. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608
6. Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378:487–497
7. Herold KC, Gitelman SE, Ehlers MR et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62:3766–3774
8. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152
9. Rigby MR, Harris KM, Pinckney A et al (2015) Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 125:3285–3296
10. Gitelman SE, Gottlieb PA, Rigby MR et al (2013) Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 1:306–316
11. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV (1986) Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 315:215–219
12. Miller KM, Foster NC, Beck RW et al (2015) Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 38:971–978
13. Simon G, Parker M, Ramiya V et al (2008) Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57:405–414
14. Eisenbarth GS, Srikanta S, Jackson R et al (1985) Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 2:271–276
15. Saudek F, Havrdova T, Boucek P, Karasova L, Novota P, Skibova J (2004) Polyclonal anti-T cell therapy for type 1 diabetes mellitus of recent onset. Rev Diabet Stud 1:80–88
16. Greenbaum CJ, Beam CA, Boulware D et al (2012) Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 61:2066–2073
17. Bellin MD, Barton FB, Heitman A et al (2012) Potent induction immunotherapy promotes long-term insulin independence after islet transplantation in type 1 diabetes. Am J Transplant 12:1576–1583
18. Couri CE, Oliveira MC, Stracieri AB et al (2009) C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301:1573–1579
19. Li L, Shen S, Ouyang J et al (2012) Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves beta-cell function in Chinese patients with new onset of type 1 diabetes. J Clin Endocrinol Metab 97:1729–1736
20. Snarski E, Milczarczyk A, Torosian T et al (2011) Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 46:562–566
21. D'Addio F, Valderrama Vasquez A, Ben Nasr M et al (2014) Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. Diabetes 63:3041–3046
22. Haller MJ, Gitelman SE, Gottlieb PA et al (2015) Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes. J Clin Invest 125:448–455